DERMIRA, INC. More news
| Managers | Title | Age | Since |
|---|---|---|---|
| President | - | 20-02-19 | |
Carly Loeb
COO | Chief Operating Officer | - | 17-12-31 |
Gary Thompson
CMP | Compliance Officer | - | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Philip Johnson
BRD | Director/Board Member | 59 | 20-02-19 |
Gordon Brooks
BRD | Director/Board Member | - | 20-02-19 |
| President | - | 20-02-19 |
Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis. The Company's portfolio consists of QBREXZA and Lebrikizumab. QBREXZA is a once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients. QBREXZA is applied directly to the skin and is designed to block underarm sweat production by inhibiting sweat gland activation. Lebrikizumab is an injectable, humanized monoclonal antibody targeting interleukin 13 (IL-13) that the Company is developing for the treatment of moderate-to-severe atopic dermatitis.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.86% | 22.2B | |
| -16.53% | 21.23B | |
| -8.49% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
